Literature DB >> 27185067

Nonlinear response surface in the study of interaction analysis of three combination drugs.

Wen Wan1, Xin-Yan Pei2, Steven Grant2, Jeffrey B Birch3, Jessica Felthousen2, Yun Dai2, Hong-Bin Fang4, Ming Tan4, Shumei Sun1.   

Abstract

Few articles have been written on analyzing three-way interactions between drugs. It may seem to be quite straightforward to extend a statistical method from two-drugs to three-drugs. However, there may exist more complex nonlinear response surface of the interaction index (II) with more complex local synergy and/or local antagonism interspersed in different regions of drug combinations in a three-drug study, compared in a two-drug study. In addition, it is not possible to obtain a four-dimensional (4D) response surface plot for a three-drug study. We propose an analysis procedure to construct the dose combination regions of interest (say, the synergistic areas with II≤0.9). First, use the model robust regression method (MRR), a semiparametric method, to fit the entire response surface of the II, which allows to fit a complex response surface with local synergy/antagonism. Second, we run a modified genetic algorithm (MGA), a stochastic optimization method, many times with different random seeds, to allow to collect as many feasible points as possible that satisfy the estimated values of II≤0.9. Last, all these feasible points are used to construct the approximate dose regions of interest in a 3D. A case study with three anti-cancer drugs in an in vitro experiment is employed to illustrate how to find the dose regions of interest.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Genetic algorithm (GA); Interaction index (II); Model robust regression (MRR); Synergism; Three-drug combination; Viability

Mesh:

Year:  2016        PMID: 27185067      PMCID: PMC5148726          DOI: 10.1002/bimj.201500021

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  14 in total

1.  Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures.

Authors:  Ming Tan; Hong-Bin Fang; Guo-Liang Tian; Peter J Houghton
Journal:  Stat Med       Date:  2003-07-15       Impact factor: 2.373

Review 2.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

Review 3.  Interactions between drugs and occupied receptors.

Authors:  Ronald J Tallarida
Journal:  Pharmacol Ther       Date:  2006-09-07       Impact factor: 12.310

4.  Confidence Intervals of Interaction Index for Assessing Multiple Drug Interaction.

Authors:  J Jack Lee; Maiying Kong
Journal:  Stat Biopharm Res       Date:  2009-02-01       Impact factor: 1.452

5.  Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.

Authors:  Hong-Bin Fang; Guo-Liang Tian; Wei Li; Ming Tan
Journal:  J Biopharm Stat       Date:  2009-07       Impact factor: 1.051

6.  Evaluation of synergism or antagonism for the combined action of antiviral agents.

Authors:  J Sühnel
Journal:  Antiviral Res       Date:  1990-01       Impact factor: 5.970

Review 7.  The search for synergy: a critical review from a response surface perspective.

Authors:  W R Greco; G Bravo; J C Parsons
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

8.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

9.  Drug interaction: focusing on response surface models.

Authors:  Soo-Il Lee
Journal:  Korean J Anesthesiol       Date:  2010-05-29

10.  Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.

Authors:  Hong-Bin Fang; Douglas D Ross; Edward Sausville; Ming Tan
Journal:  Stat Med       Date:  2008-07-20       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.